Intercept Pharmaceuticals, Inc.

NasdaqGS:ICPT Stock Report

Market Cap: US$794.7m

Intercept Pharmaceuticals Dividend

Dividend criteria checks 0/6

Intercept Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.37
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Intercept cuts debt further with deal to exchange convertible notes

Sep 02

Intercept reduces debt with repurchases of $327.9M convertible notes

Aug 19

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Aug 13

Intercept Pharma Q2 2022 Earnings Preview

Aug 02

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Jul 07

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

May 23

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

May 11
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.


Dividend Yield vs Market

Intercept Pharmaceuticals Dividend Yield vs Market
How does ICPT dividend yield compare to the market?
SegmentDividend Yield
Company (ICPT)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (ICPT)0%

Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ICPT's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ICPT has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.